Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion A/S, a clinical-stage TechBio company based in Copenhagen, has recently unveiled promising new preclinical data for its off-the-shelf therapeutic vaccine, EVX-04, aimed at treating acute myeloid leukemia (AML). This innovative vaccine is developed using Evaxion's proprietary AI-Immunology™ platform, which utilizes artificial intelligence to identify and target specific tumor antigens. The announcement, made on June 11, 2026, highlights EVX-04's potential to significantly enhance treatment options for patients suffering from this aggressive form of leukemia.

Understanding EVX-04 and Its Mechanism

The EVX-04 vaccine specifically targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens derived from what is referred to as the dark genome. This term describes genetic material that is not typically expressed in normal tissues but is present in certain tumors, making it an attractive target for therapeutic interventions. The preclinical data indicates that EVX-04 is completely expressed in human cells, demonstrating correct transcription and translation processes. Furthermore, the vaccine is secreted in these cells, which is crucial for immune recognition and subsequent activation.

The significance of this data cannot be overstated. It reveals that all ERV antigens included in EVX-04 elicit specific immune responses in both mice (in vivo) and human cells (in vitro), across various human immune profiles. This capability suggests that the vaccine could effectively mediate targeted cell-killing, positioning EVX-04 as a promising candidate for a new therapeutic cancer vaccine.

Evaxion plans to present these findings at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, on June 13, 2026. The presentation will provide an opportunity for the company to discuss the implications of its research and the potential for EVX-04 to alter the treatment landscape for AML patients.

The Landscape of Acute Myeloid Leukemia

Acute myeloid leukemia is characterized by the rapid proliferation of undifferentiated myeloid precursor cells in the bone marrow, leading to poor patient outcomes, particularly for those who are not eligible for intensive chemotherapy or stem cell transplantation. This aggressive hematologic malignancy is the most common form of leukemia, predominantly affecting older adults, with a median age of diagnosis at 68 years.

Approximately 50% of AML patients are typically not fit for intensive treatment, resulting in a reliance on low-intensity chemotherapy as the standard of care. Unfortunately, remissions are often short-lived, with a reported three-year overall survival rate of only 25%. This stark statistic underscores the urgent need for novel and less toxic treatment strategies, such as those being explored with EVX-04.

Why it matters

The development of EVX-04 represents a significant advancement in the treatment of AML, particularly given the challenges faced by patients who cannot undergo traditional therapies. By utilizing AI to identify and select ERV antigens, Evaxion's approach not only enhances the specificity of the immune response but also ensures broad tumor coverage across different patients. This off-the-shelf vaccine is designed for immediate administration following diagnosis, which could streamline treatment processes and improve patient outcomes.

Moreover, the implications of Evaxion's findings extend beyond AML. The principles behind the AI-Immunology™ platform could be applied to other cancers where immunotherapies have yet to show adequate effectiveness. As the field of cancer treatment continues to evolve, the integration of artificial intelligence in vaccine development may pave the way for more personalized and effective therapeutic options.

As the data from Evaxion continues to unfold, it will be crucial for both creators and technologists in the biomedical field to monitor these developments. The intersection of AI and immunology holds the potential to transform cancer treatment paradigms, offering hope to patients who face limited options and poor prognoses. The upcoming presentation at the EHA congress will likely shed further light on the viability and future direction of EVX-04, as well as its potential role in reshaping the landscape of cancer therapeutics.